Moneycontrol Be a Pro
Get App
SENSEX NIFTY
you are here:

AstraZeneca Pharma Ltd.

BSE Live

Dec 12, 11:57
2710.00 33.30 (1.24%)
Volume
AVERAGE VOLUME
5-Day
1,977
10-Day
2,229
30-Day
2,650
151
  • Prev. Close

    2676.70

  • Open Price

    2661.30

  • Bid Price (Qty.)

    2706.00 (5)

  • Offer Price (Qty.)

    2712.00 (3)

NSE Live

Dec 12, 11:58
2706.30 30.60 (1.14%)
Volume
AVERAGE VOLUME
5-Day
33,147
10-Day
41,310
30-Day
36,080
4,134
  • Prev. Close

    2675.70

  • Open Price

    2690.00

  • Bid Price (Qty.)

    2706.60 (1)

  • Offer Price (Qty.)

    2709.90 (1)

ANNOUNCEMENTS ON AstraZeneca

  • Dec 04, 2019 17:34 Source: BSE

    AstraZeneca Pharma - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Pursuant to the Regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we hereby inform you that a one-on-one meeting is scheduled to be held with following analysts/investment managers, as per the details attached

  • Dec 04, 2019 16:19 Source: BSE

    AstraZeneca Pharma - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

    Pursuant to Regulation 39(3) of SEBI (LODR) Regulations, 2015, the Company is intimating the request received relating to Loss of share certificate and issue of duplicate share certificate as per attached details

  • Nov 27, 2019 14:36 Source: NSE

    AstraZeneca Pharma India Limited

    AstraZeneca Pharma India Limited has informed the Exchange a copy of disclosure of Related Party Transactions for half year ended September 30, 2019 under Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

  • Nov 27, 2019 14:15 Source: BSE

    AstraZeneca Pharma - Disclosure Of Related Party Transactions

    Pursuant to the provisions of Regulation 23 (9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we enclose herewith the disclosure of Related Party Transactions for half year ended September 30, 2019 for your information and records.

  • Oct 30, 2019 15:41 Source: BSE

    AstraZeneca Pharma - Intimation Regarding Chairmanship Of Stakeholders' Relationship Committee

    Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform that Ms. Revathy Ashok (DIN: 00057539), Non-Executive Independent Director, has stepped down from the position of Chairman of Stakeholders' Relationship Committee in the Company with effect from October 28, 2019. Ms. Revathy Ashok however continues as a Member of the said Committee. The aforesaid change is in view of election made by Ms. Revathy Ashok pursuant to Regulation 26 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with regard to the maximum number of Committees (across all public companies) in which a director may hold Chairmanship position. We request you to please take the above intimation on record. The Company will keep the stock exchanges informed on election of new chairman to the Stakeholders' Relationship Committee in due course.

  • Oct 25, 2019 17:32 Source: BSE

    AstraZeneca Pharma - Announcement under Regulation 30 (LODR)-Newspaper Publication

    Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose advertisements given in Business Standard and Udayavani on October 25, 2019 in respect of Board Meeting of the Company to be held on November 11, 2019.

  • Oct 24, 2019 17:20 Source: BSE

    AstraZeneca Pharma - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, November 11, 2019

    ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2019 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2019. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from Sep 16, 2019 to November 13, 2019 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.

  • Oct 21, 2019 18:20 Source: BSE

    AstraZeneca Pharma - Launch Of Durvalumab (Imfinzi) In India

    We refer to our communication dated June 21, 2018 with regard to the receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for durvalumab (Imfinzi™). With regard to the same, we now wish to update that AstraZeneca Pharma India Limited will launch durvalumab (Imfinzi™) in India on October 22, 2019. Durvalumab (Imfinzi™) provides a treatment option for patients with locally advanced, unresectable Non-Small Cell Lung Cancer (NSCLC) and metastatic urothelial carcinoma. Durvalumab (Imfinzi™) is a product of AstraZeneca global. As of April 30, 2019, durvalumab is approved in 18 countries for urothelial cancer and over 30 countries for NSCLC including US, EU, Japan and Brazil.

  • Sep 25, 2019 18:00 Source: BSE

    This is to inform that AstraZeneca Pharma India Limited has received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets. The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®) in India, subject to the receipt of other related statutory approvals and licenses. FDC of Dapagliflozin 10mg + Saxagliptin 5mg is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus (T2DM).

  • Sep 25, 2019 18:00 Source: BSE

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Aug 07, 2019
Remark : Quarterly Results & Interim Dividend